<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37843">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02613871</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-337-1655</org_study_id>
    <nct_id>NCT02613871</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection</brief_title>
  <official_title>A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the antiviral efficacy, safety, and tolerability of
      ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 12 weeks in
      chronic genotype 1 or 2 HCV infected adults who are co-infected with HBV in Taiwan.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with sustained virologic response (SVR) 12 Weeks after discontinuation of therapy (SVR12)</measure>
    <time_frame>Posttreatment Week 12</time_frame>
    <description>SVR12 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) at 12 Weeks after stopping study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of any adverse event leading to permanent discontinuation of study drug</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with SVR at 4 Weeks after discontinuation of therapy (SVR4)</measure>
    <time_frame>Posttreatment Week 4</time_frame>
    <description>SVR4 is defined as HCV RNA &lt; LLOQ at 4 weeks after stopping study treatment, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HCV RNA &lt; LLOQ while on treatment and during posttreatment follow-up</measure>
    <time_frame>Up to Posttreatment Week 108</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA change from baseline while on treatment</measure>
    <time_frame>Baseline and up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with virologic failure</measure>
    <time_frame>Up to Posttreatment Week 12</time_frame>
    <description>Virologic failure is defined as :
Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ while on treatment), or
Rebound (confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or
Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)
Relapse (HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA &lt; LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HBV DNA change from baseline while on treatment and during posttreatment follow-up</measure>
    <time_frame>Baseline and up to Posttreatment Week 108</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg level change from baseline while on treatment and during posttreatment follow-up</measure>
    <time_frame>Baseline and up to Posttreatment Week 108</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Lysyl oxidase-like 2 (LOXL-2) change from baseline while on treatment and during posttreatment follow-up</measure>
    <time_frame>Baseline and up to Posttreatment Week 108</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that require HBV therapy</measure>
    <time_frame>Up to Posttreatment Week 108</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis status as assessed by Fibroscan® at posttreatment Weeks 12, 60, and 108</measure>
    <time_frame>Posttreatment Weeks 12, 60, and 108</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that develop hepatocellular carcinoma (HCC)</measure>
    <time_frame>Up to Posttreatment Week 108</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>LDV/SOF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF FDC for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDV/SOF</intervention_name>
    <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily</description>
    <arm_group_label>LDV/SOF</arm_group_label>
    <other_name>Harvoni®</other_name>
    <other_name>GS-5885/GS-7977</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Individuals with chronic genotype 1 or 2 HCV and HBV coinfection

          -  Individuals must not be taking or require treatment with HBV antiviral therapy at
             screening. For participants that are HBV treatment experienced, the most recent
             treatment must have been completed at least 6 months prior to Day 1.

          -  Cirrhosis determination by Fibroscan

          -  Screening laboratory values within defined thresholds

          -  Use of two effective contraception methods if female or male is of childbearing
             potential

        Key Exclusion Criteria:

          -  Current or prior history of clinically-significant illness or any other major medical
             disorder that may interfere with individual's treatment, assessment or compliance
             with the protocol

          -  Pregnant or nursing female

          -  Infection with human immunodeficiency virus (HIV) or Hepatitis Delta virus (HDV)

          -  Hepatocellular carcinoma (HCC) or other malignancy

          -  Current or prior history of clinical hepatic decompensation

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chia-Yi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiayi County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Keelung Town</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipai</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 19, 2017</lastchanged_date>
  <firstreceived_date>November 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
